VolitionRx's Nu.Q® Cancer Test Shows Prognostic Value in Lung Cancer Study

VolitionRx Limited has announced the release of new clinical study data indicating the prognostic value of its Nu.Q® Cancer Assay for patients newly diagnosed with lung cancer. This multi-national epigenetics company, with operations in both the United States and Europe, aims to enhance understanding of disease progression and patient outcomes through blood-based testing.

The study utilized a Nu.Q®-based blood test designed to detect specific cancer-related biomarkers. Findings suggest the assay can help predict a patient's likelihood of survival over a defined period or remaining free from disease progression. Further details on the test's applications and its ability to differentiate between cancer types or stages are available in the study's publication.

VolitionRx focuses on developing accessible and cost-effective blood tests for cancer. The company's objective is to improve cancer detection and monitoring by providing tools that can aid healthcare professionals in treatment decisions. These latest research findings are intended to bolster the clinical utility of the Nu.Q® technology.

Based on these results, VolitionRx expects the Nu.Q® Cancer Assay to potentially support better patient stratification and personalized treatment strategies in the future. The company plans to continue its research and development efforts to expand the test's applicability across various cancer types and care pathways.